This interview is sponsored by Biotheranostics, Inc., a Hologic company. Views and opinions expressed by speakers are their own and do not represent those of Biotheranostics, Inc., A Hologic Company.
Historically, oncologists have used clinical features to determine which HR+, early-stage breast cancer survivors will benefit from taking anti-estrogen therapy beyond year 5. However, these features do not necessarily predict benefit. The Breast Cancer Index® test can predict who is likely to benefit from longer treatment.
Ask your healthcare provider about the test and watch the full interview here:
https://www.youtube.com/watch?v=VwZCFGR8zm8
#breastcancerindex #breastcancersurvivor #antiestrogentherapy
#breastcancerawareness